Puma Biotechnology (PBYI) Cash from Operations (2010 - 2026)

Puma Biotechnology (PBYI) has 17 years of Cash from Operations data on file, last reported at 15416000.0 in Q1 2026.

• Quarterly Cash from Operations rose 326.8% year-over-year to 15416000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53606000.0 (up 71.35% YoY) and the FY2025 annual result came in at 41802000.0, up 7.41% from the prior year.
• Cash from Operations grew to 15416000.0 in Q1 2026, from 14419000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 17259000.0 in Q3 2022 to a low of 26895000.0 in Q1 2022.
• A 5-year average of 6312823.53 and a median of 10455000.0 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations sank 18648.65% — and 2025, when it jumped 1271.18%.
• Tracing PBYI's Cash from Operations over 5 years: stood at 7683000.0 in 2022, then surged by 36.08% to 10455000.0 in 2023, then jumped by 49.28% to 15607000.0 in 2024, then decreased by 7.61% to 14419000.0 in 2025, then increased by 6.91% to 15416000.0 in 2026.
• The last three Cash from Operations figures came in at 15416000.0 (Q1 2026), 14419000.0 (Q4 2025), and 9689000.0 (Q3 2025), per Business Quant data.